Trial Profile
Effect of prolonged release fampridine on quality of life, walking speed and functional goal attainment in people with severe MS related walking impairment.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jan 2020
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 28 Oct 2017 Results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
- 12 Dec 2015 New trial record
- 13 Sep 2014 Interim results (n=56) presented at the 30th Congress of the European Committee for Treatment and Research in Multiple Sclerosis